Oligonucleotide-mediated gene editing for neuromuscular disorders

Area of Science:

• Biotechnology
• Genetic Engineering
• Neuromuscular Disorders

Background:

• Duchenne muscular dystrophy (DMD) is a severe neuromuscular disorder.
• Gene replacement therapy is one approach, but oligonucleotide-mediated gene editing presents an alternative.

Purpose of the Study:

• To review the mechanisms, potential, hurdles, and results of oligonucleotide-mediated gene editing for muscular dystrophies.
• To highlight the progress and future directions for this therapeutic strategy.

Main Methods:

• Review of current literature on oligonucleotide-mediated gene editing.
• Analysis of mechanisms for inducing single base pair alterations in the dystrophin gene.
• Evaluation of delivery systems, toxicity, and production scalability.

Main Results:

• Oligonucleotide-mediated gene editing can restore dystrophin gene expression in skeletal muscle.
• Significant progress has been made in understanding repair mechanisms and oligonucleotide production.
• Potential for permanent and effective treatment of DMD.

Conclusions:

• Oligonucleotide-mediated gene editing holds significant promise for treating DMD.
• Overcoming challenges in precision, delivery, and safety is essential for clinical translation.
• Advancements in production scalability facilitate the move from research to clinical application.